Word

SK PHARMTECO

Status

Registered

Status Code

700

Status Date

Tuesday, February 16, 2021

Serial Number

88740759

Registration Number

6269493

Registration Date

Tuesday, February 16, 2021

Mark Type

3000

Filing Date

Friday, December 27, 2019

Published for Opposition

Tuesday, December 1, 2020

Trademark Owner History

SK INC. -
SK HOLDINGS CO., LTD - Original Registrant

Classifications

5 Pharmaceutical and veterinary preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; dietetic food supplements, namely, dietetic foods adapted for medical purposes, dietetic food adapted for veterinary use; sanitary preparations for medical purposes; biological preparations for medical purposes, namely, for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; biochemical preparations for medical purposes, namely, for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; chemical preparations for pharmaceutical purposes, namely, for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; Preparations of trace elements for human and animal use, namely, nutritional supplements; ferments for pharmaceutical purposes; biotechnological preparations for medical purposes, namely, for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; blood solvent, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; chemical preparations for medicinal purposes, namely, for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; chemical preparations for medical or veterinary purposes, namely, for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; chemical preparations for sanitary use; Pharmaceutical preparations, namely, immunomodulators; vitamin preparations; vaccines; Dietary and nutritional supplements; therapeutic drugs and agents for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, inflammatory diseases, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain and psychiatric disorder; bacteriological preparations for medical and veterinary use

The color(s) red and orange is/are claimed as a feature of the mark.
The mark consists of the letters "SK" in red stylized font and the letters "pharmteco" in orange stylized font. To the top right of the "SK" portion of the mark is a design of wings. The inner portion of the wings is red, and the outer portion of the wings is orange. White is not claimed as a feature of the mark and only represents background or transparent areas.

Trademark Events

Jul 7, 2021

Automatic Update Of Assignment Of Ownership

Feb 16, 2021

Registered-Principal Register

Dec 1, 2020

Official Gazette Publication Confirmation E-Mailed

Dec 1, 2020

Published For Opposition

Nov 11, 2020

Notification Of Notice Of Publication E-Mailed

Oct 24, 2020

Approved For Pub - Principal Register

Oct 9, 2020

Teas/Email Correspondence Entered

Oct 9, 2020

Correspondence Received In Law Office

Oct 3, 2020

Assigned To Lie

Aug 28, 2020

Teas Response To Office Action Received

Mar 22, 2020

Notification Of Non-Final Action E-Mailed

Mar 22, 2020

Non-Final Action E-Mailed

Mar 22, 2020

Non-Final Action Written

Mar 21, 2020

Assigned To Examiner

Jan 7, 2020

Notice Of Design Search Code E-Mailed

Jan 4, 2020

New Application Office Supplied Data Entered In Tram

Dec 31, 2019

New Application Entered In Tram